FDA clears Dexcom G6 Pro CGM

Thursday, October 10, 2019

SAN DIEGO – Dexcom’s G6 Pro CGM has received clearance from the U.S. Food and Drug Administration, allowing healthcare professionals to use the device with their patients. The Dexcom G6 Pro is the only single use, professional CGM that gathers real-time glucose data over a 10-day period, and offers both a blinded and un-blinded mode. The data allows providers to adjust a patient’s therapy and help them modify daily behavior. “At Dexcom, we are continuing to drive innovation in wearable health technology,” said Kevin Sayer, president, CEO and chairman of Dexcom. “Using the power of Dexcom G6 Pro, clinicians can use the insights gained from a 10-day professional CGM session to adjust treatment plans and empower their patients to live healthier lives.”